DMDenis O' Mahony

Denis O' Mahony

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Denis O' Mahony has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fall-risk-increasing drug use in older community-dwelling adults: prevalence, association with fall-related admissions and post-discharge prescribing changes—a retrospective cohort study

    by Steven Gilmore, Ann Sinéad Doherty, Frank Moriarty, Fiona Boland, Caroline McCarthy, Ryan Muddiman, Barbara Clyne, Tom Fahey, Denis O’MAhony, Emma Wallace

    Background: Fall-risk-increasing drugs (FRIDs) may contribute to a higher falls-risk in older people, but research examining standardised screening tools is limited. Objectives: To examine FRID prevalence in community-dwelling older adults, any association with subsequent fall-related hospital admissions, and FRID prescriptions before and after admission. Design: Retrospective cohort study. Subjects/setting: Adults aged ≥65 years across 44 general practices in Ireland. Methods: Fourteen FRIDs, defined by Screening Tool of Older Persons Prescriptions in older adults with high Fall risk (STOPPFall) criteria, were examined as time-varying exposures from 2012 to 2016. The association between FRID exposure and fall-related admissions was estimated using Cox proportional hazards models, adjusted for relevant confounders. Participants’ FRID use pre- and post-fall-related admission was analysed descriptively. Findings: Of the 35 942 participants, 16 780 (47%) were prescribed at least one long-term FRID at baseline, and 867 (2.4%) experienced a subsequent fall-related admission. Long-term FRID use was associated with a higher risk of fall-related admission [adjusted hazard ratio (aHR) 2.85, 95% CI 2.13–3.82, P < .001], demonstrating a stronger association with an increasing FRID burden—one FRID: aHR 2.81 (95% CI 2.07–3.82, P < .001); ≥5 FRIDs: 5.67 (95% CI 3.70–8.70, P < .001). Long-term FRID prevalence measured pre- and post-fall-related admission was unchanged (53.9%–53.2%). A total of 148 (19.5%) participants had a FRID discontinued, 86 (11.3%) were prescribed an additional FRID and 110 (14.5%) had a FRID initiated for the first time. Conclusion: FRID use, defined via STOPPFall, was prevalent in older adults and associated with a substantially increased risk of injurious falls. FRID use remained unchanged following discharge. Guidelines recommend including medication review in fall-risk assessments, but further work is needed to embed this across health systems.

  • Response to Boland et al. “Appraisal of the references supporting STOPP/START version 3 criteria”

    by Denis O’MAhony, Antonio Cherubini, Anna Renom Guiteras, Michael Denkinger, Jean-Baptiste Beuscart, Graziano Onder, Adalsteinn Gudmundsson, Alfonso J. Cruz-Jentoft, Wilma Knol, Gülistan Bahat, et al.


  • Open Access

    Characterising prescribing cascades in older community-dwelling adults attending general practice in The Netherlands: a retrospective cohort study

    by Ann Sinéad Doherty, Marieke Perry, Frank Moriarty, Fiona Boland, Barbara Clyne, Tom Fahey, Denis O’MAhony, Emma Wallace

    Background: Prescribing cascades, where one medication is used to treat/prevent the adverse effects of another, have been the subject of increased research focus. However, few studies have confirmed potential prescribing cascades identified via administrative or dispensed medicines records with general practice patient record data. This study examined the incidence of ThinkCascades, a list of nine prescribing cascades of clinical relevance in older adults developed via international expert consensus, using general practice data in The Netherlands. Methods: A retrospective cohort study examined prescribing records for adults aged ≥ 65 years captured within the FaMe-Net general practice database in The Netherlands for the period 2011–2021. The primary exposures were incident use of Drug A within each ThinkCascades dyad, with the primary outcomes defined as incident use of the corresponding Drug B within 365 days. Independent clinical review of identified potential prescribing cascades was conducted by a general practitioner and pharmacist using an approach consistent with methods applied in earlier prescribing cascade research. Results: The eligible cohort comprised 710 incident users of any ThinkCascades Drug A. Their mean age was 75.8 (SD = 6.1) years; 53.5% ( n = 380) were female. Overall, 21 ThinkCascades dyads were identified in 18 participants, representing a one-year incidence proportion of 2.5% ( N = 710). Only six of nine ThinkCascades were identified amongst study participants, most commonly the calcium channel blocker to diuretic prescribing cascade. Just over one-quarter of identified potential prescribing cascades (6/21; 28.6%) were supported as true prescribing cascades based on independent clinical record review. True cascade likelihood was indeterminable for three cases. Conclusions: Prescribing cascades, defined by ThinkCascades, were relatively uncommon over the eight-year study of older people attending Dutch general practice. Three of nine ThinkCascades were not identified. Only one in four identified prescribing cascades had evidence supporting a true prescribing cascade following independent clinical record review. Further research to characterise the prevalence of confirmed prescribing cascades is required. Recent research recommends expanding the number of prescribing cascade dyads which may impact identification rates. Tools to support prescribing cascade awareness, identification and deprescribing need to incorporate shared decision-making with patients and demonstrate clinical utility in supporting medication reviews in primary care.


  • Open Access

    Prevalence and impact of prescribing cascades in community‐dwelling adults: Longitudinal analysis of the Irish longitudinal study on ageing (TILDA)

    by Ann Sinéad Doherty, Rose Anne Kenny, Frank Moriarty, Fiona Boland, Barbara Clyne, Tom Fahey, Denis O' Mahony, Emma Wallace

    Prescribing cascades occur when medication is prescribed to prevent/treat the adverse effects of another medication and may be intentional/unintentional. This study examines the prevalence of nine prescribing cascades (ThinkCascades) in The Irish Longitudinal StuDy on Ageing (TILDA). A prospective cohort study examined those aged ≥50 years with three consecutive data collection waves ( N = 6118) recorded between Wave 1 (2009/2011) and Wave 5 (2018). Nine separate analysis sets were created, representing each ThinkCascade. Exposure was the incident use of Drug A at wave x. A prescribing cascade was defined as the incident use of Drug B at wave x + 1, with continued use of Drug A. Five out of nine ThinkCascades were identified over 9 years of follow‐up. Overall, 24 participants experienced at least one ThinkCascade, representing a 2.1% prevalence ( n = 1153 eligible). This low prevalence may indicate prescribers' awareness of prescribing cascades. Higher event rates are required to examine any association with adverse health outcomes.


  • Open Access

    Association Between Hyponatremia and Mortality and Readmission in Multimorbid Older Adults—A Cohort Study

    by Seraina Netzer, Viktoria Gastens, Benoît Boland, Carole E. Aubert, Corlina J. A. Huibers, Wilma Knol, Anne Spinewine, Denis O’mahony, Drahomir A. Aujesky, Mirjam Christ-Crain, et al.

    Background/Objectives: Hyponatremia has been associated with mortality and hospital readmissions. Although multimorbid older patients are particularly affected, specific data on this group are lacking. Methods: A prospective cohort was used based on the OPERAM (OPtimising thERapy to prevent Avoidable hospital admissions in the Multimorbid elderly) trial, a European multicenter, cluster-randomized trial among hospitalized patients aged ≥70 years with ≥3 chronic medical conditions taking ≥5 long-term medications, with documented sodium values at admission, excluding participants with hypernatremia (>145 mmol/L). The primary outcome was all-cause 1-year mortality, and secondary outcomes were 30-day mortality and readmission at 1 year and at 30 days. We examined the association between hyponatremia and mortality in comparison to normonatremia using a mixed-effects survival model, with adjustment for age, sex, comorbidities, study intervention arm, study site and cluster; and the association between hyponatremia and readmission using competing risk models with death as the competing risk. Subgroup analyses were performed across sodium hyponatremia categories (mild 134–130 mmol/L, moderate 129–125 mmol/L, severe < 125 mmol/L). Results: Of 2008 OPERAM participants, 1968 had a sodium value at admission, and 33 were excluded due to hypernatremia. In the 1935 participants, the mean age was 79.4 years (standard deviation 6.3), 866 (44.8%) were female, the median number of comorbidities was 11 (IQR 8–16), the median number of drugs was 10 (IQR 7–13), and 401 (20.7%) had hyponatremia at admission. The multivariate-adjusted hazard ratio (HR) for 1-year mortality with hyponatremia was 1.41 (95% confidence interval [CI] 1.11–1.78, 364 deaths) and for 30-day mortality was 1.20 (95%CI 0.74–1.94, 89 deaths). The adjusted sub-HR for 1-year readmission was 0.94 (95%CI 0.79–1.11), and that for 30-day readmission was 1.1 (95%CI 0.78–1.59). There was a linear increase in 1-year mortality across hyponatremia categories (HR from 1.31 to 2.64, p for trend = 0.001). Conclusions: Hyponatremia at admission is associated with increased 1-year mortality in multimorbid older adults, with increasing risk for lower sodium values. These findings support sodium as a useful prognostic marker in this setting, while its potential independent impact on survival remains to be clarified in prospective studies.


  • Open Access

    Prevalence of potentially inappropriate prescribing in community-dwelling older adults: an application of STOPP/START version 3 to The Irish Longitudinal Study on Ageing (TILDA)

    by Ann Sinéad Doherty, Frank Moriarty, Fiona Boland, Barbara Clyne, Tom Fahey, Rose Anne Kenny, Denis O’mAhony, Emma Wallace

    Purpose: Potentially inappropriate prescribing includes prescribing potentially inappropriate medicines (PIMs), where risk of medication-related harm may outweigh the clinical benefit(s), and potential prescribing omissions (PPOs), whereby clinically indicated medications are unprescribed without good reason. This study aimed to assess prevalence of PIMs and PPOs (subset of STOPP/START version 3) in older community-dwelling adults and any association with healthcare utilisation and functional decline over time. Methods: Retrospective cohort study of a nationally representative longitudinal study of ageing in Ireland (n = 3619) (2016–2018). Logistic regressions examined association of patient characteristics with PIMs/PPOs and between prevalent PIMs/PPOs and functional decline. Negative binomial regressions examined association between PIM/PPO with healthcare utilisation over time. Results: Participants’ mean age was 74.2 years (SD 6.99), 53.9% were female and were prescribed a mean of 4.02 (SD 3.16) medications. A total of 1123 (31.0%) participants experienced STOPP PIMs and 1309 (36.2%) START PPOs. STOPP PIMs were associated with increased hospital admissions (adjusted incident rate ratio (aIRR) 1.38, 95% confidence interval (CI) 1.08, 1.75), and functional decline (adjusted odds ratio (aOR) 1.46, 95% CI 1.11, 1.91) at follow-up. Age ≥ 75 years (aOR 1.32, 95% CI 1.10, 1.57) and three or more chronic conditions (aOR 5.19, 95% CI 3.69, 7.31) were significantly associated with START PPOs. Conclusion: Approximately one-third of study participants experienced STOPP PIMs, associated with an increased risk of hospital admissions and functional decline. START PPOs also occurred in over one-third, associated with increasing age and degree of multimorbidity. Balancing the risk: benefit of medications for older people with multimorbidity remains challenging.


  • Deprescribing in cognitively vulnerable older people: development and validation of STOPPCog criteria

    by Siobhan McGettigan, Denis Curtin, Denis O’mAhony

    Objective: To validate STOPPCog, a list of explicit criteria for potentially inappropriate medication use in cognitively vulnerable older adults. Design: A Delphi consensus survey of an expert panel comprising academic geriatricians, old age psychiatrists, general practitioners, and clinical pharmacists. Setting: Ireland. Subjects: Nine panellists. Methods: STOPPCog criteria were initially created by the authors based on clinical experience and literature appraisal. Criteria were organised according to drug/drug class. Using Delphi consensus methodology, panellists ranked their agreement with each criterion on a 5-point Likert scale and provided written feedback. Criteria with a median value of 1 or 2 (strongly agree/agree) and a 25th centile value of ≤2 were included in the final list. Results: All panellists completed two Delphi consensus validation rounds. Twenty-five criteria were proposed initially, twenty were accepted. One criterion was rejected (multi-vitamin supplements), and four criteria were rephrased (two of these were combined to one criterion for greater clarity). The final list comprised 23 criteria that are arranged in six subgroups i.e. (i) drugs with anticholinergic properties taken daily; (ii) drugs with sedative properties taken daily; (iii) drugs that may exacerbate psychotic symptoms in patients with alpha-synuclein pathology; (iv) drugs used for chronic pain; (v) drugs without proven efficacy for dementia taken daily; (vi) drugs that are of no proven benefit in advanced stage dementia i.e. clinical dementia rating of 3.0 where palliation may be appropriate. Conclusion: STOPPCog comprises 23 criteria relating to medications that are potentially inappropriate in cognitively vulnerable older adults. STOPPCog may assist physicians in deprescribing medications in this patient population.


  • Open Access

    Correction: The association between medication use and health-related quality of life in multimorbid older patients with polypharmacy

    by Charlotte Falke, Fatma Karapinar, Marcel Bouvy, Mariëlle Emmelot, Svetlana Belitser, Benoit Boland, Denis O’mAhony, Kevin D. Murphy, Moa Haller, Paola Salari, et al.


  • Open Access

    The association between medication use and health-related quality of life in multimorbid older patients with polypharmacy

    by Charlotte Falke, Fatma Karapinar, Marcel Bouvy, Mariëlle Emmelot, Svetlana Belitser, Benoit Boland, Denis O’mAhony, Kevin D. Murphy, Moa Haller, Paola Salari, et al.

    Purpose: To explore the association between medication use-related factors and health-related quality of life (HRQoL) in older hospitalised multimorbid patients with polypharmacy. Methods: This cross-sectional study used the intervention arm data of the OPERAM trial (hospitalised patients ≥ 70 years with polypharmacy). HRQoL was assessed using the visual analogue scale (EQ-VAS) and the EQ-5D index score of the EuroQol questionnaire (EQ-5D-5L). Lower or higher EQ-VAS/EQ-5D was based on the median of the study population. Medication use-related factors included hyperpolypharmacy (≥ 10 medications), anticholinergic and sedative burden, appropriateness of medication (STOPP/START criteria), high-risk medication for hospital (re)admission, medication complexity and adherence. Multivariable logistic regression analysis was used to assess the association between medication use-related factors and HRQoL. Results: A total of 955 patients were included (mean age 79 years, 46% female, median EQ-VAS of 60, median EQ-5D of 0.60). Opioids use was associated with lower EQ-5D and EQ-VAS (aOR EQ-5D: 2.10; 95% CI 1.34–3.32, EQ-VAS: 1.59; 1.11–2.30). Hyperpolypharmacy (aOR 1.37; 1.05–1.80), antibiotics (aOR 1.64; 1.01–2.68) and high medication complexity (aOR 1.53; 1.10–2.15) were associated with lower EQ-VAS. A high anticholinergic and sedative burden (aOR 1.73; 1.11–2.69), presence of multiple prescribing omissions (aOR 1.94; 1.19–3.17) and benzodiazepine use (aOR 2.01; 1.22–3.35) were associated with lower EQ-5D. Especially in hyperpolypharmacy patients, high anticholinergic and sedative burden and medication complexity were associated with a lower HRQoL. Conclusion: Several medication use-related factors are significantly associated with a lower HRQoL in hospitalised older patients. Medication complexity is a novel factor, which should be considered when evaluating medication use of older patients with hyperpolypharmacy.